MABPHARM-B

Mabpharm staged a rebound from intraday lows, recovering from 0.365 HKD to close at 0.395 HKD in the afternoon session, down 5.95% from the previous close of 0.420 HKD. The turnaround was driven by the company's full-year net profit of 57.13 million RMB, marking a return to profitability, which attracted buying interest near the 52-week low. Despite the stock trading 55.11% below its 52-week high of 0.88 HKD and down 21% YTD, Q4 revenue surged 159.61% YoY to 207 million HKD, with net profit up 286.62% YoY, reflecting fundamental improvement. However, the stock remains below both its MA20 (0.402 HKD) and MA60 (0.437 HKD), suggesting lingering technical headwinds.